Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Chae, Yee Soo | - |
dc.contributor.author | Baek, Sun Kyung | - |
dc.contributor.author | Kang, Seok Yun | - |
dc.contributor.author | Park, Sarah | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Lee, Soohyeon | - |
dc.contributor.author | Sohn, Joo Hyuk | - |
dc.contributor.author | Park, Yeon-Hee | - |
dc.contributor.author | Im, Young-Hyuck | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.date.accessioned | 2021-09-03T19:11:57Z | - |
dc.date.available | 2021-09-03T19:11:57Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87300 | - |
dc.description.abstract | Purpose The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio (LNR) in patients with breast cancer after neoadjuvant chemotherapy. Materials and Methods This retrospective analysis is based on the data of 814 patients with stage breast cancer treated with four cycles of doxorubicin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical significance of LNR (3 categories: low 0-0.20 vs. intermediate 0.21-0.65 vs, high 0.66-1.00) using a Cox proportional regression model. Results A total of 799 patients underwent breast surgery. Pathologic complete response (pCR, ypTO/isNO) was achieved in 129 patients (16.1%) (hormone receptor [HR] +/human epidermal growth factor receptor 2 [HER2]-, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; triple negative breast cancer, 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range, 0 to 42) and 13.98 (range, 1 to 64), respectively. The mean LNR was 0.17 (low, 574 [71.8%]; intermediate, 170 [21.3%]; high, 55 [6.9%]). In univariate analysis, LNR showed significant association with a worse relapse-free survival (3-year relapse-free survival rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; p < 0.001, log-rank test). In multivariate analysis, LNR did not show significant association with recurrence after adjusting for other clinical factors (age, histologic grade, subtype, ypT stage, ypN stage, lymphatic or vascular invasion, and pCR). In subgroup analysis, the LNR system had good prognostic value in HR+/HER2- subtype. Conclusion LNR is not superior to ypN stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy. However, the prognostic value of the LNR system in HR+/HER2patients is notable and worthy of further investigation. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | DISEASE-FREE SURVIVAL | - |
dc.subject | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject | LYMPH-NODES | - |
dc.subject | SUBTYPES | - |
dc.title | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.contributor.affiliatedAuthor | Lee, Soohyeon | - |
dc.identifier.doi | 10.4143/crt.2015.475 | - |
dc.identifier.scopusid | 2-s2.0-84996605671 | - |
dc.identifier.wosid | 000385212800022 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.4, pp.1373 - 1381 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1373 | - |
dc.citation.endPage | 1381 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002154715 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | DISEASE-FREE SURVIVAL | - |
dc.subject.keywordPlus | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | LYMPH-NODES | - |
dc.subject.keywordPlus | SUBTYPES | - |
dc.subject.keywordAuthor | Lymph nodes | - |
dc.subject.keywordAuthor | Lymph node excision | - |
dc.subject.keywordAuthor | Neoadjuvant therapy | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.